Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 45

-Paragraph 13

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 4

-Subparagraph (b)(1)

-URI http://asc.fasb.org/extlink&oid=6851643&loc=d3e12069-110248

Name:	us-gaap_GuaranteeObligationsMaximumExposure
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Significant Accounting Policies (Details 4) (USD $) In Millions, unless otherwise specified	9 Months Ended	12 Months Ended	9 Months Ended		1 Months Ended
	Sep. 30, 2012 item	Dec. 31, 2011 item	Sep. 30, 2012 Maximum	Sep. 30, 2012 Regulus Therapeutics Inc.	Oct. 31, 2012 Regulus Therapeutics Inc. Maximum
Equity method of accounting
Principal plus accrued interest guaranteed on Regulus convertible notes				$ 5.6
Suspended net losses				$ 2.7
Ownership percentage after stock sale			20.00%		20.00%
Consolidation of variable interest entities
Number of variable interest entities in which the entity is not primary beneficiary	6	6